Replies to post #8351 on YaSheng Group (HERB)

[surfer44]

From a tiny OTC shell to a mid-size biotech company. This venture capital investment paid off. :-)

Cellular Biomedicine Group, Inc, a wholly-owned subsidiary of CBMG Holdings, develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.

Our technology includes 2 major cell platforms:

01
Immune Cell therapy for treatment of a broad range of cancers using Cancer Vaccines, Chimeric Antigen Receptor T cell (“CAR-T”), TCR-T and TIL Technologies
02
Human adipose-derived mesenchymal progenitor cells (“haMPC”) for treatment of joint and autoimmune diseases
Our primary research and manufacturing facilities are located in China. Our cellular platforms are based on technologies developed both in-house and obtained through acquisition, licensing and collaboration arrangements with other companies.

[RealDutch]

The reason why I wanted to know the size of ProMab is because if it had been a $300M company with HERB investing say $50M in Jove, then the money would have to come from somewhere. And it would have to come from the plantations. This would invalidate my assumption that parent is exiting.

But it is so small that even HERB as they are now (in the filings) can support it.

The old, the big Yasheng would have picked a much bigger company to merge with. So my theory that Parent is exiting is still valid. And we should focus on the plantations worth billions. And the art worth 100's of millions. This biotech venture is small relative to that.